Revisão Revisado por pares

Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?

2008; Oxford University Press; Volume: 23; Issue: 8 Linguagem: Inglês

10.1093/ndt/gfn267

ISSN

1460-2385

Autores

Dorine W. Swinkels, Jack F.M. Wetzels,

Tópico(s)

Hemoglobinopathies and Related Disorders

Resumo

The introduction of erythropoiesis-stimulating agents(ESA), such as recombinant human erythropoietin (EPO)has allowed effective treatment of anaemia in patients withchronic kidney disease (CKD). However, the optimal tar-get level of haemoglobin is debated and many patients areresistant to ESA.Hepcidin is a recently discovered low-molecular-weightprotein that plays an important role in iron metabolism.Hepcidin may be relevant in CKD and explain the often-observed disbalance in iron metabolism and the resistanceto ESA. As such hepcidin could become an important toolto predict ESA responsiveness and to guide treatment withESA and intravenous iron. In addition, hepcidin has thepotential to become a target of treatment. In this review wesummarize the pathophysiology of hepcidin and discuss itspotential relevance for patients with CKD.

Referência(s)